Squarepoint’s Cytek Biosciences CTKB Stock Holding History

Squarepoint’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$367K	Buy	82,776 +57,480	+227%	+$245K	﹤0.01%	3673
2026 Q1	$111K	Buy	+25,296	New	+$119K	﹤0.01%	4049
2025 Q4	–	Sell	-158,641	Closed	-$550K	–	4368
2025 Q3	$550K	Buy	158,641 +13,590	+9%	+$51K	﹤0.01%	3158
2025 Q2	$493K	Buy	145,051 +102,047	+237%	+$340K	﹤0.01%	3294
2025 Q1	$172K	Sell	43,004 -24,911	-37%	-$129K	﹤0.01%	4071
2024 Q4	$441K	Sell	67,915 -42,666	-39%	-$254K	﹤0.01%	3830
2024 Q3	$613K	Sell	110,581 -76,780	-41%	-$435K	﹤0.01%	2952
2024 Q2	$1.05M	Buy	187,361 +170,539	+1,014%	+$1.02M	﹤0.01%	2521
2024 Q1	$113K	Buy	+16,822	New	+$133K	﹤0.01%	3777
2023 Q2	–	Sell	-30,773	Closed	-$283K	–	3632
2023 Q1	$283K	Sell	30,773 -54,660	-64%	-$588K	﹤0.01%	2607
2022 Q4	$872K	Buy	+85,433	New	+$1.15M	﹤0.01%	1915

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Squarepoint's CTKB Position: Q2 2026 in Review

Squarepoint increased its Cytek Biosciences (CTKB) stake by 227% in Q2 2026, buying an estimated $245K and bringing the position to 82,776 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #3673.

Squarepoint first reported a position in CTKB in Q4 2022 and has held it in 11 quarters since. The position peaked at $1.05M in Q2 2024. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Squarepoint held 82,776 shares of Cytek Biosciences worth $367K as of Q2 2026.
Squarepoint bought 57,480 Cytek Biosciences shares in Q2 2026, an estimated $245K.
Cytek Biosciences made up ﹤0.01% of Squarepoint's portfolio in Q2 2026, its #3673 holding.
Squarepoint first reported a position in Cytek Biosciences in Q4 2022 and has held it in 11 quarters since.
Squarepoint's Cytek Biosciences position peaked at $1.05M in Q2 2024.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.